Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment

Emcure Pharma receives CDSCO approval to market Poviztra for fatty liver treatment.

Poviztra contains innovator semaglutide for progressive liver disease.

Approval expands access to a new option for patients with limited prior treatments.